Securities Fraud Class Action Filed Against ImmunityBio, Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 15 2026
0mins
Source: PRnewswire
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio, Inc. (NASDAQ:IBRX) on behalf of investors who purchased shares between January 19, 2026, and March 24, 2026, highlighting serious concerns regarding the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false and misleading statements during this period, particularly regarding the capabilities of its cancer vaccine Anktiva, which misled investors about the company's prospects and could negatively impact its stock price and market trust.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price, raising investor concerns about corporate governance and compliance.
- Investor Action Recommendations: Investors are encouraged to apply for lead plaintiff status by May 26, 2026, to represent all affected investors, indicating a focus on the company's future legal and financial responsibilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.740
Low
5.00
Averages
7.33
High
9.00
Current: 7.740
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's ANKTIVA Therapy Economic Analysis Reveals Significant Cost Savings
- Significant Cost Savings: ImmunityBio's analysis indicates that ANKTIVA plus BCG can save up to $151,438 per cystectomy avoided in a U.S. Medicare population, highlighting the therapy's potential to reduce healthcare expenditures.
- Comparative Efficacy Advantage: The complete response rate for ANKTIVA plus BCG stands at 49.6%, surpassing TAR-200's 45.9%, while also incurring lower treatment and administration costs, showcasing ANKTIVA's competitive edge in treating BCG-unresponsive NMIBC patients.
- Economic Model Support: The findings are derived from a cost-consequence model utilizing data from ImmunityBio's QUILT-3.032 study and TAR-200's SunRISe-1 trial, emphasizing the potential of ANKTIVA plus BCG to deliver durable responses while lowering costs to the healthcare system.
- Optimistic Investor Sentiment: ImmunityBio's stock has surged 291% year-to-date and 192% over the past 12 months, reflecting a positive investor reaction to the economic analysis results and indicating strong market confidence in the company's future growth.
See More
Securities Fraud Class Action Filed Against ImmunityBio, Inc.
- Lawsuit Announcement: On May 22, 2026, Kessler Topaz Meltzer & Check, LLP announced a securities fraud class action against ImmunityBio, Inc. (NASDAQ:IBRX) for investors who purchased shares between January 19 and March 24, 2026, highlighting serious concerns about the company's financial health.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false and misleading statements during this period, particularly regarding the capabilities of its cancer vaccine Anktiva, leading to investor misconceptions about the company's prospects, which could adversely affect its stock price and market trust.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by its executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price to $7.42 per share, demonstrating the direct impact of regulatory risks on the company's valuation.
- Investor Action Recommendation: Investors are advised to apply for lead plaintiff status in the class action by May 26, 2026, to represent all affected investors, indicating that the legal risks faced by the company could lead to broader financial losses.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting significant risks in the company's information disclosure practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its promotional materials misleadingly suggested Anktiva could cure all cancers without data support, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to submit claims, indicating that the company's legal risks could impact future financing and market trust.
- Public Health Impact: The FDA warned that ImmunityBio's misleading promotions pose a public health threat, emphasizing the need for the company to adhere to stricter compliance standards in product marketing to avoid further legal and financial repercussions.
See More
Study Reveals Treatment Preferences in High-Risk Bladder Cancer Patients
- Diverse Patient Preferences: A study involving 86 UK patients with high-risk non-muscle-invasive bladder cancer (NMIBC) reveals that treatment preferences are highly individualized, shaped by personal experiences, values, and age, underscoring the importance of personalized care.
- Impact of BCG Treatment: Patients currently receiving BCG are more likely to favor bladder-sparing strategies, while those who have undergone radical cystectomy are more supportive of repeating that decision, reflecting the complexity and individual differences in treatment choices.
- Quality of Life Considerations: The study indicates significant variations in lifestyle disruption and quality-of-life considerations among patients, with male participants expressing greater concern about the daily-life impact of radical cystectomy, suggesting that medical decisions must integrate patient quality of life.
- Clinical Effectiveness Priority: Clinical effectiveness, including impacts on recurrence, progression, and life expectancy, is identified as the most critical factor influencing treatment decisions, demonstrating patients' trade-offs between cancer control and quality of life in their treatment choices.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiation: ImmunityBio, Inc. (NASDAQ: IBRX) faces a class action lawsuit for purchasers of its securities between January 19 and March 24, 2026, with a deadline of May 26, 2026, to apply as lead plaintiff, alleging violations of the Securities Exchange Act of 1934 by the company and its Executive Chairman.
- False Statement Allegations: The lawsuit claims that ImmunityBio made false and misleading statements during the class period, particularly regarding its lead biologics product Anktiva, asserting it could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated.
- FDA Warning Letter Impact: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock highlighted misleading advertising for Anktiva, resulting in a 21% drop in stock price, indicating a significant loss of market confidence in the company.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, showcasing its strong capabilities and influence in securities class action lawsuits.
See More
ImmunityBio Faces Class Action Lawsuit Over Misleading Claims
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased ImmunityBio securities between January 19 and March 24, 2026, have until May 26, 2026, to seek lead plaintiff status in a class action lawsuit, indicating significant investor concern over potential misconduct by the company.
- Allegations Overview: The lawsuit alleges that ImmunityBio and its Executive Chairman made false or misleading statements during the class period, claiming that their lead product Anktiva could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated, potentially undermining investor confidence.
- FDA Warning Impact: On March 24, 2026, a warning letter from the FDA to ImmunityBio's CEO highlighted misleading advertising of Anktiva, resulting in a 21% drop in stock price following the news, reflecting market apprehension regarding the company's compliance and regulatory standing.
- Law Firm Credentials: Robbins Geller is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, showcasing its significant strength and influence in the securities class action landscape.
See More
ImmunityBio's ANKTIVA Therapy Economic Analysis Reveals Significant Cost Savings
- Significant Cost Savings: ImmunityBio's analysis indicates that ANKTIVA plus BCG can save up to $151,438 per cystectomy avoided in a U.S. Medicare population, highlighting the therapy's potential to reduce healthcare expenditures.
- Comparative Efficacy Advantage: The complete response rate for ANKTIVA plus BCG stands at 49.6%, surpassing TAR-200's 45.9%, while also incurring lower treatment and administration costs, showcasing ANKTIVA's competitive edge in treating BCG-unresponsive NMIBC patients.
- Economic Model Support: The findings are derived from a cost-consequence model utilizing data from ImmunityBio's QUILT-3.032 study and TAR-200's SunRISe-1 trial, emphasizing the potential of ANKTIVA plus BCG to deliver durable responses while lowering costs to the healthcare system.
- Optimistic Investor Sentiment: ImmunityBio's stock has surged 291% year-to-date and 192% over the past 12 months, reflecting a positive investor reaction to the economic analysis results and indicating strong market confidence in the company's future growth.
See More
Securities Fraud Class Action Filed Against ImmunityBio, Inc.
- Lawsuit Announcement: On May 22, 2026, Kessler Topaz Meltzer & Check, LLP announced a securities fraud class action against ImmunityBio, Inc. (NASDAQ:IBRX) for investors who purchased shares between January 19 and March 24, 2026, highlighting serious concerns about the company's financial health.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false and misleading statements during this period, particularly regarding the capabilities of its cancer vaccine Anktiva, leading to investor misconceptions about the company's prospects, which could adversely affect its stock price and market trust.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by its executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price to $7.42 per share, demonstrating the direct impact of regulatory risks on the company's valuation.
- Investor Action Recommendation: Investors are advised to apply for lead plaintiff status in the class action by May 26, 2026, to represent all affected investors, indicating that the legal risks faced by the company could lead to broader financial losses.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting significant risks in the company's information disclosure practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its promotional materials misleadingly suggested Anktiva could cure all cancers without data support, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to submit claims, indicating that the company's legal risks could impact future financing and market trust.
- Public Health Impact: The FDA warned that ImmunityBio's misleading promotions pose a public health threat, emphasizing the need for the company to adhere to stricter compliance standards in product marketing to avoid further legal and financial repercussions.
See More
Study Reveals Treatment Preferences in High-Risk Bladder Cancer Patients
- Diverse Patient Preferences: A study involving 86 UK patients with high-risk non-muscle-invasive bladder cancer (NMIBC) reveals that treatment preferences are highly individualized, shaped by personal experiences, values, and age, underscoring the importance of personalized care.
- Impact of BCG Treatment: Patients currently receiving BCG are more likely to favor bladder-sparing strategies, while those who have undergone radical cystectomy are more supportive of repeating that decision, reflecting the complexity and individual differences in treatment choices.
- Quality of Life Considerations: The study indicates significant variations in lifestyle disruption and quality-of-life considerations among patients, with male participants expressing greater concern about the daily-life impact of radical cystectomy, suggesting that medical decisions must integrate patient quality of life.
- Clinical Effectiveness Priority: Clinical effectiveness, including impacts on recurrence, progression, and life expectancy, is identified as the most critical factor influencing treatment decisions, demonstrating patients' trade-offs between cancer control and quality of life in their treatment choices.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiation: ImmunityBio, Inc. (NASDAQ: IBRX) faces a class action lawsuit for purchasers of its securities between January 19 and March 24, 2026, with a deadline of May 26, 2026, to apply as lead plaintiff, alleging violations of the Securities Exchange Act of 1934 by the company and its Executive Chairman.
- False Statement Allegations: The lawsuit claims that ImmunityBio made false and misleading statements during the class period, particularly regarding its lead biologics product Anktiva, asserting it could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated.
- FDA Warning Letter Impact: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock highlighted misleading advertising for Anktiva, resulting in a 21% drop in stock price, indicating a significant loss of market confidence in the company.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, showcasing its strong capabilities and influence in securities class action lawsuits.
See More
ImmunityBio Faces Class Action Lawsuit Over Misleading Claims
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased ImmunityBio securities between January 19 and March 24, 2026, have until May 26, 2026, to seek lead plaintiff status in a class action lawsuit, indicating significant investor concern over potential misconduct by the company.
- Allegations Overview: The lawsuit alleges that ImmunityBio and its Executive Chairman made false or misleading statements during the class period, claiming that their lead product Anktiva could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated, potentially undermining investor confidence.
- FDA Warning Impact: On March 24, 2026, a warning letter from the FDA to ImmunityBio's CEO highlighted misleading advertising of Anktiva, resulting in a 21% drop in stock price following the news, reflecting market apprehension regarding the company's compliance and regulatory standing.
- Law Firm Credentials: Robbins Geller is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, showcasing its significant strength and influence in the securities class action landscape.
See More
